ArticleMolecular biology reports2026
Knockdown of FAXDC2 promotes cell proliferation, migration, invasion and EMT in HepG2 cells by upregulating c-Met and its phosphorylation.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most common malignant diseases with high morbidity and mortality rates, and the lack of effective therapeutic targets limits the clinical treatment efficacy. Fatty acid hydroxylase domain containing 2 (FAXDC2) regulates the synthesis of cholesterol and sphingomyelin and promotes cancer development in various types of cancer. However, the role and mechanism of FAXDC2 on HCC still remained to be clarified.
methodsTCGA-LIHC database was utilized to identify the expression of FAXDC2 and its effect on the prognosis in HCC patients. The efficiency of FAXDC2 knockdown interfered by siRNA in HepG2 cells was detected by western blot and qPCR. CCK-8, colony formation, transwell migration and invasion assays were used to evaluate the functions of FAXDC2 on cell proliferation, migration and invasion in HepG2 cells. Western blot and qPCR were applied to examine the expression of epithelial-mesenchymal trasnsition (EMT)-related markers and c-Met signaling pathway. Furthermore, c-Met knockdown by siRNA and c-Met activity inhibition by Tepotinib were used to explore the regulatory relationship between FAXDC2 and c-Met in HCC cells.
resultsThe FAXDC2 mRNA level was downregulated in the liver tissues of HCC patients and its expression was significantly correlated with clinical stage. The lower FAXDC2 expression in the HCC patients was associated with a poor prognosis. FAXDC2 knockdown promoted cell proliferation, migration, invasion, and EMT in HepG2 cells. Interestingly, we found that FAXDC2 knockdown not only upregulated the expression of c-Met, but promoted its phosphorylation. Above all, both knockdown of c-Met and Tepotinib-mediated c-Met activity inhibition significantly counteracted cell proliferation, migration, invasion, and EMT of HepG2 cells caused by knocking down FAXDC2.
conclusionsFAXDC2 acts as a tumor suppressor in HCC, and its knockdown promotes cell proliferation, migration, invasion, and EMT via upregulating c-Met expression and enhancing its phosphorylation in HepG2 cells. Therefore, the FAXDC2/c-Met axis may serve as a noval potential therapeutic target for HCC intervention.
Indexed as
Identifiers
42053668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.